Elafibranor approved to treat adults with a rare liver disease known as primary biliary cholangitis

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved elafibranor (Iqirvo) to treat adult patients with a rare type of liver disease known as primary biliary cholangitis (PBC).